Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Department of Physiology, Monash University, Melbourne, Victoria, Australia.
Exp Physiol. 2015 Jul 1;100(7):796-804. doi: 10.1113/EP085250.
What is the central question of this study? What is the potential role of endothelial NO production via overexpression of the l-arginine transporter, CAT1, as a mitigator of cardiac hypertrophy? What is the main finding and its importance? Augmentation of endothelium-specific l-arginine transport via CAT1 can attenuate pressure-overload-dependent cardiac hypertrophy and fibrosis. Our findings support the conclusion that interventions that improve endothelial l-arginine transport may provide therapeutic utility in the setting of myocardial hypertrophy. Such modifications may be introduced by exercise training or locally delivered gene therapy, but further experimental and clinical studies are required. Endothelial dysfunction has been postulated to play a central role in the development of cardiac hypertrophy, probably as a result of reduced NO bioavailability. We tested the hypothesis that increased endothelial NO production, mediated by increased l-arginine transport, could attenuate pressure-overload-induced cardiac hypertrophy. Echocardiography and blood pressure measurements were performed 15 weeks after transverse aortic constriction (TAC) in wild-type (WT) mice (n = 12) and in mice with endothelium-specific overexpression of the l-arginine transporter, CAT1 (CAT+; n = 12). Transverse aortic constriction induced greater increases in heart weight to body weight ratio in WT (by 47%) than CAT+ mice (by 25%) compared with the respective controls (P ≤ 0.05). Likewise, the increase in left ventricular wall thickness induced by TAC was significantly attenuated in CAT+ mice (P = 0.05). Cardiac collagen type I mRNA expression was greater in WT mice with TAC (by 22%; P = 0.03), but not in CAT+ mice with TAC, compared with the respective controls. Transverse aortic constriction also induced lesser increases in β-myosin heavy chain mRNA expression in CAT+ mice compared with WT (P ≤ 0.05). Left ventricular systolic pressure after TAC was 36 and 39% greater in WT and CAT+ mice, respectively, compared with the respective controls (P ≤ 0.001). Transverse aortic constriction had little effect on left ventricular end-diastolic pressure in both genotypes. Taken together, these data indicate that augmenting endothelial function by overexpression of l-arginine transport can attenuate pressure-overload-induced cardiac hypertrophy.
这项研究的核心问题是什么?通过过表达 l-精氨酸转运蛋白 CAT1 来增加内皮细胞一氧化氮生成,作为减轻心脏肥大的潜在作用是什么?主要发现及其重要性是什么?通过 CAT1 增强内皮细胞特异性 l-精氨酸转运可以减轻压力超负荷依赖性心肌肥大和纤维化。我们的研究结果支持这样的结论,即改善内皮细胞 l-精氨酸转运的干预措施可能在心肌肥大的情况下具有治疗效用。这种修饰可以通过运动训练或局部基因治疗来实现,但还需要进一步的实验和临床研究。已经提出内皮功能障碍在心脏肥大的发展中起核心作用,可能是由于一氧化氮生物利用度降低所致。我们测试了以下假设,即通过增加 l-精氨酸转运来增加内皮细胞一氧化氮生成,可以减轻压力超负荷引起的心肌肥大。在野生型(WT)小鼠(n = 12)和内皮细胞特异性过表达 l-精氨酸转运蛋白 CAT1 的小鼠(CAT+;n = 12)中,在横主动脉缩窄(TAC)后 15 周进行超声心动图和血压测量。与各自的对照组相比,WT 小鼠(增加 47%)的心脏重量与体重比增加大于 CAT+小鼠(增加 25%)(P ≤ 0.05)。同样,TAC 诱导的左心室壁厚度增加在 CAT+小鼠中显著减弱(P = 0.05)。与各自的对照组相比,TAC 诱导的 WT 小鼠心脏胶原 I 型 mRNA 表达增加(增加 22%;P = 0.03),但 CAT+小鼠中没有增加。与 WT 相比,CAT+小鼠的β-肌球蛋白重链 mRNA 表达增加较少(P ≤ 0.05)。与各自的对照组相比,WT 和 CAT+小鼠的左心室收缩压在 TAC 后分别增加了 36%和 39%(P ≤ 0.001)。在两种基因型中,TAC 对左心室舒张末期压力几乎没有影响。综上所述,这些数据表明,通过过表达 l-精氨酸转运来增强内皮功能可以减轻压力超负荷引起的心肌肥大。